Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia.
A double-blind, placebo-controlled study in eight healthy male volunteers was conducted to study possible disulfiram-type reactions and hypoprothrombinemia associated with cefotetan administration. Three doses of cefotetan (2 g) or of placebo were administered at 12-h intervals. Ethanol (0.5 g/kg of total body weight) was ingested 1 h after the third dose. Blood ethanol, serum acetaldehyde, and prothrombin times were measured throughout the study. Heart rate, blood pressure, and clinical signs as well as symptoms suggestive of a disulfiram-type reaction were also noted. Five of eight volunteers that received cefotetan showed significant flushing. A significant increase in heart rate also was noted. No change in mean arterial pressure was observed during the cefotetan phase, and no one experienced nausea or vomiting. No statistical differences were observed between phases with respect to ethanol area under the time-concentration curve, elimination rate, or serum acetaldehyde concentrations. A slight but statistically significant increase in prothrombin time also was observed with cefotetan. This study suggests that patients receiving cefotetan might be at risk to develop disulfiram-type reactions and hypoprothrombinemia.
D000079:Acetaldehyde / Q000493:pharmacokinetics; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D015313:Cefotetan; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects*; D004221:Disulfiram / Q000494:pharmacology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004347:Drug Interactions; D000431:Ethanol / Q000493:pharmacokinetics / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D011516:Prothrombin / Q000097:blood*; D011517:Prothrombin Time
D002513:Cephamycins; D000431:Ethanol; D015313:Cefotetan; D011516:Prothrombin; D000079:Acetaldehyde; D004221:Disulfiram